← Back to Patent Explorer
US5288490A Expired / Lapsed US ⏱️ 0.0 years remaining

Thrombus-targeted complexes of plasminogen activator and fibrin fragments

Assignee: Temple University
•
Filing: 1991-11-25
•
Granted: 1994-02-22
•
Expires: 2011-11-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Thrombolytic hybrids are formed as covalent or non-covalent complexes of fibrin fragments and plasminogen activator molecules. Native plasmin degradation fragments of fibrin or non-native fibrin fragments are covalently or non-covalently linked to plasminogen activators such as t-PA, scu-PA, urokinase, streptokinase, and the like. Useful native fibrin fragments which may be utilized to form complexes with plasminogen activators include fragments E1, E2, E3, D and DD, and (DD)E complex. The fibrin fragment component targets the hybrid to vascular thrombi, immobilizing the plasminogen activator molecule onto the fibrin surface of the thrombus. Once localized on a thrombus surface, the plasminogen activator component of the hybrid activates only the clot-surface bound plasminogen transported by the fibrin fragment vehicle, without significant systemic activation of plasminogen. The hybrids are strong potentiators of plasminogen activator activity, generating more plasmin from fibrin-surface bound plasminogen than the plasminogen activator molecule alone. The hybrids have a longer half-life in circulation than the corresponding unprotected plasminogen activator molecules.

Inventors

  • 👤 Andrei Z. Budzynski
  • 👤 Linda C. Knight
  • 👤 Ahmed A. Hasan

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 04:02
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6456; A; A61; A61K; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/49; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/75

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 25 words
A thrombolytic agent comprising a non-covalent complex formed from contacting tPA with a 100-500 molar excess of either fibrin fragment DD or fibrin fragment DD(E).
Claim 2
Dependent Claim 25 words
A thrombolytic agent comprising a non-covalent complex formed from contacting tPA with a 100-500 molar excess of either fibrin fragment DD or fibrin fragment DD(E).
Claim 3
Dependent Claim 15 words
A thrombolytic agent according to claim 1, wherein tPA is complexed with fibrin fragment DD.
Claim 4
Dependent Claim 15 words
A thrombolytic agent according to claim 1, wherein tPA is complexed with fibrin fragment DD(E).
Claim 5
Dependent Claim 16 words
A thrombolytic agent comprising tPA covalently linked to either fibrin fragment DD or fibrin fragment DD(E).
Claim 6
Dependent Claim 16 words
A thrombolytic agent comprising tPA covalently linked to either fibrin fragment DD or fibrin fragment DD(E).
Claim 7
Dependent Claim 16 words
A thrombolytic agent according to claim 4, wherein tPA is covalently linked to fibrin fragment DD.
Claim 8
Dependent Claim 16 words
A thrombolytic agent according to claim 4, wherein tPA is covalently linked to fibrin fragment DD(E).
Claim 9
Dependent Claim 26 words
A thrombolytic agent according to claim 4, wherein tPA and either fibrin fragment DD or fibrin fragment DD(E) are covalently linked by a homobifunctional cross-linking agent.
Claim 10
Dependent Claim 26 words
A thrombolytic agent according to claim 4, wherein tPA and either fibrin fragment DD or fibrin fragment DD(E) are covalently linked by a heterobifunctional cross-linking agent.
Claim 11
Dependent Claim 22 words
A thrombolytic agent according to claim 8, wherein said heterobifunctional cross-linking agent is selected from the group consisting of N-succinimidyl-3-(2-pyridyldithio)propionate and sulfosuccinimidyl-2-(p-azidosalicylamido)ethyl-1-3'-dithiopropionate.
Claim 12
Dependent Claim 23 words
A composition comprising a pharmaceutically effective amount of a thrombolytic agent according to claim 1 and an inert pharmaceutically acceptable carrier or diluent.
Claim 13
Dependent Claim 18 words
A composition according to claim 10, wherein said carrier or diluent is suitable for intravascular or intramuscular administration.
Claim 14
Dependent Claim 23 words
A composition comprising a pharmaceutically effective amount of a thrombolytic agent according to claim 4 and an inert pharmaceutically acceptable carrier or diluent.
Claim 15
Dependent Claim 18 words
A composition according to claim 12, wherein said carrier or diluent is suitable for intravascular or intramuscular administration.
Claim 16
Dependent Claim 17 words
A method for dissolving vascular thrombi comprising administering a composition according to claim 10 to a mammal.
Claim 17
Dependent Claim 17 words
A method for dissolving vascular thrombi comprising administering a composition according to claim 12 to a mammal.

References Cited (Backward Citations)

US4427646A Cited
US4536391A Cited
US4564596A Cited
US4673573A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1997-02-21 1997-08-23 1998-02-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2001-02-21 2001-08-23 2002-02-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2005-02-21 2005-08-23 2006-02-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag